NCT00168389 - A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema | Biotech Hunter

Enrollment

494

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions

Diabetic Macular Edema

Interventions

DRUG

Dexamethasone

350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.

OTHER

Sham

Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.

Trial Locations (10)

Unknown

Inglewood

Westmead

Toronto

Prague

Hamburg

Tel Aviv

Rockwell Center, Makati

Coimbra

Cape Town

Barcelona